Recombinant protein expression
Express your protein using the optimal system—CHO, HEK293, E. coli, wheat-germ cell-free, or yeast. From in silico feasibility assessment to the delivery of purified batches within just a few weeks.
Our recombinant protein expression solutions
+95%
purity, with very low endotoxin levels (<0.1 EU/mg)
<4semaines
to obtain your first small-scale batches of purified protein
From µg to g
quantities, with optimized scale-up
+95%
purity, with very low endotoxin levels (<0.1 EU/mg)
<4semaines
to obtain your first small-scale batches of purified protein
From µg to g
quantities, with optimized scale-up
+95%
purity, with very low endotoxin levels (<0.1 EU/mg)
<4semaines
to obtain your first small-scale batches of purified protein
From µg to g
quantities, with optimized scale-up
The assurance of quality made in France
French scientific excellence supporting your research through customized, reliable, and responsive solutions.
Why choose RD-Biotech for your recombinant proteins?
Expertise in difficult and toxic proteins
RD-Biotech excels in the production of recombinant proteins considered particularly challenging, including membrane proteins, GPCRs, cytokines, and toxic or unstable enzymes.
Through our command of all major expression systems (E. coli, CHO, HEK293, yeast, and cell-free) we systematically identify the best strategy for obtaining a soluble, functional, and biologically active recombinant protein.
We have successfully completed numerous projects in which other platforms had failed, particularly involving therapeutic recombinant proteins and antigens used in recombinant protein vaccines.
Our multi-system approach and extensive optimization expertise make the difference in the most demanding projects.
Flexibility and customization
Every recombinant protein production project is unique. At RD-Biotech, we do not apply a standardized process. Instead, we design a customized solution based on your sequence, final application—research, diagnostics, or therapeutic development—and time or budget constraints.
Whether you require simple transient expression in HEK cells, scale-up in CHO cells, cell-free production, or extensive optimization of recombinant protein cloning and expression, our team adapts every stage to your needs.
This flexibility enables you to obtain exactly the recombinant protein you require, without compromise.
Rapid small- and medium-scale production
In research environments where speed is critical, RD-Biotech offers recombinant protein production in batches ranging from a few milligrams to several hundred milligrams, with some of the shortest lead times on the market: only a few weeks from cloning to purified protein.
Unlike large CDMOs focused on GMP manufacturing and high-volume production, our organization is designed to respond quickly to the needs of academic laboratories, biotechnology companies, and preclinical R&D teams.
You can move your projects forward faster without waiting months to receive your recombinant protein.
Dedicated technical support
With RD-Biotech, you are never on your own. You benefit from a dedicated scientific contact, Head of the Recombinant Protein Platform, or a senior expert from our immunology team.
From the initial in silico feasibility assessment through delivery of the final batch, we support you with regular technical discussions, detailed reports, and data-driven scientific recommendations.
This personalized support helps ensure the success of your recombinant protein production project while saving you valuable time.
Benefit from expert, tailor-made support for your immunology projects.
«We develop customized solutions in molecular biology, immunology, and cell engineering, with recognized expertise in recombinant antibody production. Through robust processes and a collaborative approach, we deliver highly specific biomolecules that fully meet the requirements of research and preclinical or clinical development »
Quentin Bardin, Commercial
Meet our immunology and protein biochemistry team
Magali
Head of the Antibodies, Proteins and Cells Business Unit
Romain
Head of Antibody, Protein and ELISA Activities
Anthony
Head of Vector Construction
We meet our clients’ requirements by providing advanced technical solutions while optimizing budgets.
Our expertise : a practical example
| Client : |  |
Objective: To produce a series of recombinant antibodies from sequences provided by the client and validate their functional specificity for a tumor-associated membrane target.
- Antibody reformatting from scFv to human IgG1
- Production by transient transfection in HEK293 cells, with an average yield of 80 mg/L
- Protein A affinity purification, followed by SDS-PAGE and SEC-HPLC analysis
- Characterization by ELISA, flow cytometry, and live-cell binding assays
- Delivery of a complete report complying with the client’s quality requirements
FAQ
Do you have questions about our recombinant proteins? Here is what you need to know to get your project off to a good start.
A recombinant protein is a protein produced through genetic engineering. The gene encoding the protein of interest is inserted into an expression vector and then introduced into a host system, such as a bacterium, a eukaryotic cell, or a cell-free system.
This method enables reproducible and scalable recombinant protein production tailored to your needs, whether for research, diagnostics, or therapeutic applications.
We work with five expression systems in parallel:
- E. coli
- CHO cells
- HEK cells
- Yeast
- Wheat-germ cell-free systems
This unique multi-system approach allows us to test several hosts during the pilot phase and select the most suitable system for your recombinant protein based on yield, folding, native post-translational modifications, and other requirements.
- Feasibility assessment and pilot study: 2–3 weeks
- Purified small-scale batch of 1–50 mg: 4–6 weeks in total
- Large-scale production: 6–10 weeks, depending on the expression system
Most pilot projects deliver purified batches in under three weeks.
Yes. We are particularly experienced in recombinant protein production using E. coli, offering high yields of up to 500 mg/L or more, controlled costs, and very short lead times.
This system is ideal for simple proteins, enzymes, and intracellular domains. We also offer codon optimization and periplasmic production to improve protein solubility.
Depending on the protein of interest, we can guarantee purity levels of up to 95% through multistep purification, combining affinity chromatography, ion-exchange chromatography, and size-exclusion chromatography.
We can also provide tag removal, endotoxin control below 0.1 EU/µg, and endotoxin-free or High Quality grades.
Absolutely. We regularly produce therapeutic recombinant proteins and antigens for recombinant protein vaccines in R&D, enhanced-quality, and endotoxin-free grades.
Our mammalian expression systems (CHO and HEK) as well as our yeast systems are particularly well suited to preclinical and clinical applications.
We manage the entire recombinant protein cloning and expression process, including:
- Codon optimization for the selected expression system
- Gene synthesis or subcloning
- Addition of tags such as His, Fc, AviTag, or SUMO
- Vector construction
- Sequencing
You may also provide your own expression vector.
Our wheat-germ cell-free system is often the ideal solution for toxic or membrane proteins because it avoids cellular cytotoxicity.
We systematically test several expression systems in parallel to maximize your chances of success.
Simply send us:
- Your sequence or specifications
- The required tag
- The target quantity
- The intended application
We will provide a detailed, non-binding proposal outlining the recommended strategy, timeline, and budget within 48 hours.
CHO cells are often preferred for larger-scale production and therapeutic applications. HEK293 cells are ideal for rapid testing and provide glycosylation profiles that closely resemble those found in humans.
Discover our other services
RD-Biotech has been a biotechnology CRO/CDMO since 2002. We provide customized molecular biology, immunology, and cell-engineering solutions for R&D and preclinical and clinical development, combining expertise, responsiveness, and confidentiality.
Would you like to clarify your expectations?